Valvular disease
Conditions
Interventions
Cyclopofol group:Group A: 0.3mg/kg was injected with cyclopofol pump, and 50ug of sufentanil was injected with constant speed pump. After patients fell asleep, cisatracurium was injected intravenousl
Propofol group:Group B: Target pump infusion of propofol, and 50ug of sufentanil was injected with constant speed pump. After patients fell asleep, cisatracurium was injected intravenously, and endotr
Sponsors
The First Affiliated Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: A. Patients undergoing elective heart valve replacement; B. ASA classification I-III; C. Age >=18 years old, male or female; D. NYHA grade II to III; E. Sign the informed consent form.
Exclusion criteria
Exclusion criteria: A. Allergic to or contraindicated to propofol, cyclopofol, opiates and other drugs and their components; B. Severe cardiac insufficiency, ASA level ? or above; C. Abnormal liver function: ALT and/or AST exceeding 1.5 times the upper limit of the medical reference range; D Abnormal renal function: creatinine exceeding the upper limit of the medical reference range; E. Preoperatively complicated with mental disorders; F. Heart failure within one month before surgery; G. Drug and alcohol addicts; H. Patients with difficult airway: Markov grade ? or above.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intake and exit volume;Anesthetic dosage;Vasoactive drug use;Onset time of sedatives;Pain stimulation at administration site;Intraoperative awareness;Postoperative ventilator use time;ICU stay time;Postoperative nausea and vomiting;Postoperative delirium (delirium Assessment scale); | — |
Countries
china
Contacts
Public ContactQi Mao
The First Affiliated Hospital of Guangxi Medical University
Outcome results
None listed